Expert Review of Hematology最新文献_第5页

Autoimmune cytopenias in chronic lymphocytic leukemia in the era of novel drugs. 新药时代慢性淋巴细胞白血病的自身免疫性细胞减少

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2026-06-08 DOI: 10.1080/17474086.2026.2681766

Wiktoria Ryżewska, Tadeusz Robak, Jacek Treliński, Bartosz Puła

{"title":"Autoimmune cytopenias in chronic lymphocytic leukemia in the era of novel drugs.","authors":"Wiktoria Ryżewska, Tadeusz Robak, Jacek Treliński, Bartosz Puła","doi":"10.1080/17474086.2026.2681766","DOIUrl":"10.1080/17474086.2026.2681766","url":null,"abstract":"Introduction: Autoimmune cytopenias are common complications of chronic lymphocytic leukemia, leading to increased morbidity and a reduced quality of life for affected patients. The diagnosis and management of these complications have improved with the development of new therapeutic agents for chronic lymphocytic leukemia.Areas covered: This review summarizes the key findings on diagnosing and managing autoimmune cytopenias in patients with chronic lymphocytic leukemia, with a particular focus on the impact of new therapeutic agents. These include Bruton tyrosine kinase inhibitors, B-cell lymphoma 2 protein inhibitors, monoclonal and bispecific antibodies, phosphatidylinositol 3-kinase inhibitors, and chimeric antigen receptor T-cell therapies. The review is based on a PubMed database search for articles published up to March 1, 2026, covering the abovementioned topics, as well as the authors' clinical and research experience.Expert opinion: Despite advances in the treatment of autoimmune cytopenias, current management still primarily relies on corticosteroid therapy. Clear evidence supporting the use of novel targeted agents in this setting remains limited. Future progress depends on dedicated clinical trials aimed at better defining the role of emerging therapies and enabling more personalized treatment strategies, although the rarity of autoimmune cytopenias associated with chronic lymphocytic leukemia presents a significant challenge.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"845-857"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148143269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-CD123 monoclonal antibodies as therapeutic agents for acute myeloid leukemia: a systematic review. 抗cd123单克隆抗体作为急性髓系白血病治疗剂的系统综述

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2026-06-11 DOI: 10.1080/17474086.2026.2685775

Vitória Maria Vito, Vinícius André Boff, Izabel Galhardo Demarchi, Ana Carolina Rabello de Moraes

{"title":"Anti-CD123 monoclonal antibodies as therapeutic agents for acute myeloid leukemia: a systematic review.","authors":"Vitória Maria Vito, Vinícius André Boff, Izabel Galhardo Demarchi, Ana Carolina Rabello de Moraes","doi":"10.1080/17474086.2026.2685775","DOIUrl":"10.1080/17474086.2026.2685775","url":null,"abstract":"Introduction: Acute myeloid leukemia is a hematological malignancy characterized by clonal expansion and blockade of myeloid precursor differentiation. This results in poor survival rates, particularly among older patients and those with refractory disease. CD123, the α-chain of the interleukin-3 receptor, is overexpressed in leukemic stem cells and represents a promising therapeutic target.Methods: This systematic review evaluated the efficacy and safety of anti-CD123 monoclonal antibodies administered as standalone treatment or in combination with standard care. The review adhered to the PRISMA statement and Cochrane Handbook.Results: Eight clinical trials (seven phase I/II trials and one phase III trial) that evaluated antibody-drug conjugates and bispecific antibodies met the inclusion criteria. The interventions demonstrated limited improvements in overall survival and showed frequent treatment-related toxicities such as cytokine release syndrome and dose-limiting adverse events. Most studies included heavily pretreated, relapsed, or refractory patients, which may have contributed to the poor tolerability and limited efficacy.Conclusions: Future studies should focus on conducting randomized trials with larger sample sizes and greater methodological rigor to validate the clinical utility of anti-CD123 therapies, which currently have a limited impact on overall survival.Registration: This study systematic review was prospectively registered on PROSPERO (identifier CRD4202344450.).","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"893-903"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148198053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19 associated thrombotic thrombocytopenic purpura: a case report and review of the literature. COVID-19相关血栓性血小板减少性紫癜1例报告及文献复习

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2025-02-01 DOI: 10.1080/17474086.2025.2459260

Elie Bou Sanayeh, Layal Al Mahmasani, Zaid Khamis, Salim Barakat, Carolla El Chamieh, Georges Khattar, Alexandre Matar, Firas Kreidieh, Sally Temraz

{"title":"COVID-19 associated thrombotic thrombocytopenic purpura: a case report and review of the literature.","authors":"Elie Bou Sanayeh, Layal Al Mahmasani, Zaid Khamis, Salim Barakat, Carolla El Chamieh, Georges Khattar, Alexandre Matar, Firas Kreidieh, Sally Temraz","doi":"10.1080/17474086.2025.2459260","DOIUrl":"10.1080/17474086.2025.2459260","url":null,"abstract":"Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially life-threatening complication whose association with COVID-19 is controversial. Understanding this connection is essential due to its significant impact on patient outcomes, and timely diagnosis and intervention are critical in managing this condition effectively.Areas covered: This paper presents a case of TTP triggered by COVID-19 infection in a 48-year-old female. Additionally, a comprehensive literature review was conducted using PubMed and Google Scholar databases, from inception through August 2024, to identify all published cases of COVID-19-associated TTP. The literature search focused on adult cases of TTP secondary to COVID-19 infection, highlighting the treatments used and patient outcomes.Expert opinion: In this report, we highlight the importance of recognizing TTP as a possible complication of COVID-19. While the standard treatment for TTP - plasma exchange and corticosteroids - remains the primary approach, we note that COVID-19-related cases exhibit a high risk of early relapse, as seen in our patient. The literature review suggests that TTP triggered by COVID-19 may have unique characteristics, such as a persistent low ADAMTS13 activity and increased relapse rates. Larger studies are necessary to develop optimal treatment guidelines and understand whether the presence of COVID-19 alters the typical clinical course of TTP.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"921-935"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143037782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review of laboratory methods used for analysis of von Willebrand factor and for diagnosis of related diseases. 血管性血友病因子分析及相关疾病诊断的实验室方法综述。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2025-07-04 DOI: 10.1080/17474086.2025.2525461

Jürgen Patzke, Nikolaus B Binder, Mariona Bono, François Depasse, Matthias Germer, Michael Heins, Martina Leplatoni, Stephan Schwers, Michael Spannagl, Peter L Turecek

{"title":"Review of laboratory methods used for analysis of von Willebrand factor and for diagnosis of related diseases.","authors":"Jürgen Patzke, Nikolaus B Binder, Mariona Bono, François Depasse, Matthias Germer, Michael Heins, Martina Leplatoni, Stephan Schwers, Michael Spannagl, Peter L Turecek","doi":"10.1080/17474086.2025.2525461","DOIUrl":"10.1080/17474086.2025.2525461","url":null,"abstract":"Introduction: Von Willebrand factor (VWF) is a large multimeric protein present in the blood. Its most important and best characterized function is to control bleeding in primary hemostasis, which is triggered by different biophysical mechanisms and protein-receptor interactions involving different domains of VWF. Many different diseases related to VWF, most importantly von Willebrand disease comprising different types and sub-types, require diagnosis, laboratory analysis of concentration, and function of VWF.Areas covered: As several different specific functions of VWF are physiologically relevant, several different assays are needed. The aim of this article is to provide a comprehensive overview of all relevant assays together with a description of how each assay is technically designed. Furthermore, guidance is given for choosing the right and validated assay methods.Expert opinion: This information includes technical requirements, analytical performance data, references to relevant guidelines and other guidance documents, and reference standards. Also, information on availability and the type of the assay is provided, such as automated or manual, in vitro diagnostics or research use only. Relation to the clinical use of these assays, as well as performance, and result interpretation is covered in a second article in the same issue of this journal by the same authors.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"905-919"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma. 从发作性评估到综合评估：在复发/难治性多发性骨髓瘤中整合真实世界监测。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2026-05-30 DOI: 10.1080/17474086.2026.2681764

Carmel Awadallah, Shebli Atrash, Barry Paul, Abdullah Mohammad Khan, Hira Shaikh, Christopher Strouse, Zena Chahine, Anita Mazloom, Muhammad Salman Faisal, Taha Al-Juhaishi, Omar Alkharabsheh, Prerna Mewawalla, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Jeries Kort, Alma Habib, Joseph McGuirk, Mansi R Shah, Sarah Waheed, Mahmoud AlJurf, Ghazi Alotaibi, Al-Ola Abdallah

{"title":"From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma.","authors":"Carmel Awadallah, Shebli Atrash, Barry Paul, Abdullah Mohammad Khan, Hira Shaikh, Christopher Strouse, Zena Chahine, Anita Mazloom, Muhammad Salman Faisal, Taha Al-Juhaishi, Omar Alkharabsheh, Prerna Mewawalla, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Jeries Kort, Alma Habib, Joseph McGuirk, Mansi R Shah, Sarah Waheed, Mahmoud AlJurf, Ghazi Alotaibi, Al-Ola Abdallah","doi":"10.1080/17474086.2026.2681764","DOIUrl":"10.1080/17474086.2026.2681764","url":null,"abstract":"Introduction: Patients with relapsed/refractory multiple myeloma (RRMM) now receive sequential lines of therapy over many years, generating cumulative toxicities, functional decline, and symptom burden that conventional trial endpoints and episodic clinic-based monitoring fail to capture. A synthesis of contemporary real-world monitoring strategies in RRMM is therefore needed to guide clinical practice.Areas covered: This review examines real-world monitoring strategies for RRMM, encompassing patient-reported outcome (PRO) instruments, real-world data (RWD) sources (electronic health records, claims, registries, patient-driven platforms), and digital health technologies enabling continuous between-visit assessment. Literature was identified through structured searches of PubMed and MEDLINE from January 2000 through April 2026, supplemented by manual review of reference lists and abstracts from major hematology meetings. We evaluate how these strategies complement conventional disease assessment, inform treatment sequencing in the era of CAR T-cell therapies and bispecific antibodies, and address equity gaps in monitoring access.Expert opinion: Integrating PROs, RWD, and digital health tools into routine RRMM care is a necessary evolution toward continuous, personalized disease management; coordinated investment in interoperable data infrastructure, rigorous real-world evidence frameworks, and equity-conscious implementation will be essential to translate these strategies into improved survival and quality of life for all patients.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"821-843"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148041654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Barriers to effective first-line treatment for women with iron deficiency. 对缺铁妇女进行有效一线治疗的障碍

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2026-06-03 DOI: 10.1080/17474086.2026.2683026

Kristina Rinaldi, Ding Quan Ng, Aniketh Tadepalli, Satoko Ito, George Goshua, Daniel Wang

引用次数: 0

PRDX6 knockdown sensitizes multiple myeloma cells to ferroptosis through inactivation of the PI3K/AKT pathway. PRDX6敲低通过PI3K/AKT通路失活使多发性骨髓瘤细胞对铁凋亡敏感。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2025-05-21 DOI: 10.1080/17474086.2025.2492881

Guifang Hu, Hongju Zhang, Yun Wang, Jingfeng Lu, Ke Dong, Wu Gao

{"title":"PRDX6 knockdown sensitizes multiple myeloma cells to ferroptosis through inactivation of the PI3K/AKT pathway.","authors":"Guifang Hu, Hongju Zhang, Yun Wang, Jingfeng Lu, Ke Dong, Wu Gao","doi":"10.1080/17474086.2025.2492881","DOIUrl":"10.1080/17474086.2025.2492881","url":null,"abstract":"Background: This study probes into the impact and mechanisms of PRDX6 on ferroptosis multiple myeloma (MM).Research design and methods: PRDX6 expression in MM cells were determined using Western blotting and qRT-PCR. MM cells were treated with pLKO-shPRDX6 vectors expressing PRDX6 shRNA alone or in combination with Erastin/ferrostatin-1 (ferroptosis activator/inhibitor) or 740Y-P (PI3K/AKT pathway activator). Cell viability, apoptosis, Fe2+ concentration, and ROS levels were examined using CCK-8, flow cytometric analysis, iron ion detection, and DCFH-DA assay, and ELISA. Malondialdehyde (MDA) and glutathione (GSH) levels were tested with ELISA, and SLC7A11 and GPX4 levels were measured with Western blotting.Results: PRDX6 expression was sharply increased in MM cells (p < 0.01). Silencing of PRDX6 sensitized MM cells to ferroptosis, as indicated by elevated Fe2+, ROS, and MDA levels but decreased GSH, SLC7A11, and GPX4 levels (p < 0.05), and these trends were neutralized by 740Y-P treatment. Furthermore, PRDX6 knockdown lowered the levels of PI3K/AKT pathway-associated molecules (p < 0.05).Conclusions: PRDX6 knockdown may exert pro-ferroptotic effects through inactivation of the PI3K/AKT pathway, underlying an appealing therapeutic target for MM.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"987-996"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leukapheresis versus no leukapheresis for hyperleukocytosis in acute myeloid leukemia: an updated systematic review and meta-analysis of early mortality. 急性髓性白血病中白细胞增多症的白细胞分离与无白细胞分离：早期死亡率的最新系统评价和荟萃分析。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-08-01 Epub Date: 2026-05-27 DOI: 10.1080/17474086.2026.2680138

Jamiel Reyes, Alexander Reyes

{"title":"Leukapheresis versus no leukapheresis for hyperleukocytosis in acute myeloid leukemia: an updated systematic review and meta-analysis of early mortality.","authors":"Jamiel Reyes, Alexander Reyes","doi":"10.1080/17474086.2026.2680138","DOIUrl":"10.1080/17474086.2026.2680138","url":null,"abstract":"Introduction: Leukapheresis is used for rapid cytoreduction in adults with acute myeloid leukemia (AML) and hyperleukocytosis, but its effect on early mortality remains uncertain. We performed an updated systematic review and meta-analysis of comparative studies.Methods: MEDLINE, CENTRAL, ClinicalTrials.gov, Google Scholar, and citation searching were searched from inception to March 2026. Comparative studies of leukapheresis versus no leukapheresis in adults with AML and hyperleukocytosis were included. Risk of bias was assessed using ROBINS-I, and certainty of evidence was assessed using GRADE. Random-effects meta-analysis of crude 2 × 2 data was performed using odds ratios (ORs).Results: Thirteen retrospective comparative studies were included; 10 studies comprising 1,406 patients contributed to the primary 30-day mortality analysis. Leukapheresis was not clearly associated with lower 30-day mortality compared with no leukapheresis (OR 0.94, 95% CI 0.65-1.34; I2 = 0.0%). Only one study reported an adjusted estimate. Most studies were at serious risk of bias, and certainty of evidence was very low.Conclusions: Current non-randomized evidence does not establish a reliable early-mortality benefit of leukapheresis. Confounding 3by indication remains a major limitation.Registration: This study was prospectively registered on PROSPERO (identifier: CRD420261351743).","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"811-820"},"PeriodicalIF":2.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148014201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the efficacy of erythrocytapheresis and phlebotomy in the treatment of polycythemia. 红细胞穿刺和放血治疗红细胞增多症的疗效评价。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-07-30 DOI: 10.1080/17474086.2026.2703731

Dongmei Yang, Lingli Yan, Zhenglian Luo, Xuemian Song, Jiaheng Li, Bin Han, Chunxia Chen, Bin Tan, Li Qin

{"title":"Evaluation of the efficacy of erythrocytapheresis and phlebotomy in the treatment of polycythemia.","authors":"Dongmei Yang, Lingli Yan, Zhenglian Luo, Xuemian Song, Jiaheng Li, Bin Han, Chunxia Chen, Bin Tan, Li Qin","doi":"10.1080/17474086.2026.2703731","DOIUrl":"https://doi.org/10.1080/17474086.2026.2703731","url":null,"abstract":"Background: Systematic comparison of the efficacy and safety of erythrocytapheresis and phlebotomy.Research design and methods: A retrospective analysis of 108 polycythemia patients categorized into four treatment groups: 1, 2, or 3 sessions of phlebotomy, and 1 session of erythrocytapheresis. The primary outcome was HGB change. One-way analysis of variance (ANOVA), Kruskal-Wallis H test, t-tests, and linear regression were used to compare efficacies and identify predictive factors, with subgroup analyses for polycythemia vera (PV) and high-altitude polycythemia (HAPC). Linear trend analysis was performed to evaluate the dose-response relationship.The references cited in this article were retrieved through the PUBMED database.Results: A significant difference in HGB change was observed among four groups. 3 sessions of phlebotomy were superior to 1 and 2 sessions. 1 session of erythrocytapheresis achieved comparable HGB change to 2-3 phlebotomy sessions. Linear trend analysis confirmed HGB change increased with phlebotomy sessions. In the PV subgroup, baseline HGB and female gender were predictors of HGB change. In the HAPC subgroup, only baseline HGB was a significant predictor.Conclusions: 2-3 sessions of phlebotomy are non-inferior to 1 session of erythrocytapheresis in efficacy, with higher safety and cost-effectiveness, and baseline HGB is a universal predictor of therapeutic efficacy.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148618974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early pharmacological intervention in acute promyelocytic leukemia: can we still improve outcomes? 急性早幼粒细胞白血病的早期药物干预：我们还能改善预后吗？

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2026-07-01 Epub Date: 2026-05-15 DOI: 10.1080/17474086.2026.2672111

Håkon Reikvam, Sona Vardanyan, Tor Henrik Andersson Tvedt

引用次数: 0